Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women

Expert Opinion on Investigational Drugs

Volumn 19, Issue 12, 2010, Pages 1613-1621

  Pinkerton, Joann V ^a   Stovall, Dale W ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

bazedoxifene; conjugated estrogens; estrogen; hot flashes; osteoporosis; selective estrogen receptor modulator

Indexed keywords

BAZEDOXIFENE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ETHINYLESTRADIOL; GESTAGEN; LASOFOXIFENE; LIPOPOLYSACCHARIDE; OSPEMIFENE; OSTEOCALCIN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

AMENORRHEA; BONE DENSITY; BREAST CANCER; CELL STRAIN MCF 7; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIGITAL MAMMOGRAPHY; DRUG EFFICACY; ENDOMETRIAL DISEASE; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE GENITAL SYSTEM; HOT FLUSH; HUMAN; MAMMARY GLAND; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; OVARY CANCER; OVARY CYST; PATIENT SAFETY; POSTMENOPAUSE; QUALITY OF LIFE; REVIEW; SLEEP; UTERUS BLEEDING; VAGINA ATROPHY; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; ESTROGENS, CONJUGATED (USP); FEMALE; HOT FLASHES; HUMANS; INDOLES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 78649503579     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.532487     Document Type: Review

References (33)

1. Kian Tee M, Rogatsky I, Tzagarakis-Foster C, et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell 2004;15:1262-72
2. Meegan MJ, Lloyd DG. Advances in the science of estrogen receptor modulation. Curr Med Chem 2003;10:181-210
3. McDonnell DP. The molecular determinants of estrogen receptor pharmacology. Maturitas 2004;48(Suppl 1):S7-12
4. Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34
5. Freeman EW, Sammel MD, Lin H, et al. Symptoms in the menopausal transition: hormone and behavioral correlates. Obstet Gynecol 2008;111:127-36
6. Tannen RL, Weiner MG, Xie D, et al. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod 2007;22:1769-77
7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297(13):1465-77
8. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2004;291(14):1701-12
9. Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-7
10. Ke HZ, Foley GL, Simmons HA, et al. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004;145:1996-2005
11. Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001;949:317-26
12. Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
13. Chang KC, Wang Y, Bodine PV, et al. Gene expression profiling studies of three SERMs and their conjugated estrogens combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens. J Steroid Biochem Mol Biol 2010;118(1-2):117-24
14. Kharode Y, Bodine PV, Miller CP, et al. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology 2008;149:6084-91
15. Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
16. Berrodin TJ, Chang KC, Komm BS, et al. Differential biochemical and cellular actions of Premarin estrogens: distinct pharmacology of bazedoxifene-conjugated estrogen combination. Mol Endocrinol 2009;23:74-85
17. Cerciat M, Unkila M, Garcia-Segura LM, et al. Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma- inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. Glia 2010;58:93-102
18. Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Mine Res 2008;23:525-35
19. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
20. Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16(6):1102-8
21. Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-15
22. Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009;16:1193-6
23. Van Duren D, Ronkin S, Pickar J, et al. Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies. Fertil Steril 2006;86:S88-9
24. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
25. Pickar JH, Yeh IT, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
26. Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
27. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
28. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause 2009;16:1116-24
29. Kagan R, Williams RS, Pan K, et al. A randomized, placebo- and active-controlled trial of bazedoxifene/ conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17(2):281-9
30. Utian W, Yu H, Bobula J, et al. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. Maturitas 2009;63:329-35
31. Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
32. Cushman M, Kuller LH, Prentice R, et al.; Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80
33. Available from: http://clinicaltrials.gov/ ct2/results?term= bazedoxifene+and +conjugated+estrogen [Accessed 31 May 10]